[{"id":"5561c46c-9fe6-437d-a39f-ed6b0feba556","acronym":"","url":"https://clinicaltrials.gov/study/NCT06998940","created_at":"2025-06-07T14:48:14.371Z","updated_at":"2025-06-07T14:48:14.371Z","phase":"Phase 3","brief_title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","source_id_and_acronym":"NCT06998940","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Vectibix (panitumumab) • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 01/06/2026","start_date":" 01/06/2026","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-05-31"},{"id":"f73e8116-9f3f-4e3c-8faf-7a232f425d23","acronym":"","url":"https://clinicaltrials.gov/study/NCT03861702","created_at":"2025-09-13T13:10:53.052Z","updated_at":"2025-09-13T13:10:53.052Z","phase":"Phase 2","brief_title":"Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:","source_id_and_acronym":"NCT03861702","lead_sponsor":"Nelson Yee","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 08/16/2023","primary_completion_date":" 08/16/2023","study_txt":" Completion: 09/27/2024","study_completion_date":" 09/27/2024","last_update_posted":"2025-04-18"},{"id":"79649cc6-d582-4cf7-94a7-6b84b6103cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04901702","created_at":"2021-05-25T18:52:49.387Z","updated_at":"2025-02-25T12:28:07.986Z","phase":"Phase 1/2","brief_title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT04901702","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"c5baf3d3-95f8-46cc-89ee-2ac65d9ade70","acronym":"","url":"https://clinicaltrials.gov/study/NCT06023641","created_at":"2023-09-05T18:12:33.949Z","updated_at":"2025-02-25T12:29:46.532Z","phase":"Phase 1/2","brief_title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","source_id_and_acronym":"NCT06023641","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53 • FOXO1 • MYOD1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • FOXO1 • MYOD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/13/2024","start_date":" 03/13/2024","primary_txt":" Primary completion: 10/01/2034","primary_completion_date":" 10/01/2034","study_txt":" Completion: 10/01/2037","study_completion_date":" 10/01/2037","last_update_posted":"2025-02-24"},{"id":"0a8d6efe-c307-457d-99f7-770545d57f94","acronym":"","url":"https://clinicaltrials.gov/study/NCT02631733","created_at":"2021-01-18T12:47:51.838Z","updated_at":"2025-02-25T15:25:24.826Z","phase":"Phase 1","brief_title":"Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors","source_id_and_acronym":"NCT02631733","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/31/2017","start_date":" 05/31/2017","primary_txt":" Primary completion: 11/21/2019","primary_completion_date":" 11/21/2019","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2025-02-10"},{"id":"1def5e25-f757-4960-ad8f-fdd1be50dd50","acronym":"","url":"https://clinicaltrials.gov/study/NCT03785873","created_at":"2021-01-18T18:43:16.171Z","updated_at":"2025-02-25T14:27:55.298Z","phase":"Phase 1/2","brief_title":"Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer","source_id_and_acronym":"NCT03785873","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/22/2019","start_date":" 05/22/2019","primary_txt":" Primary completion: 11/15/2024","primary_completion_date":" 11/15/2024","study_txt":" Completion: 11/15/2024","study_completion_date":" 11/15/2024","last_update_posted":"2024-12-18"},{"id":"2d9a8f08-c565-475d-9d28-781aa1dd5529","acronym":"","url":"https://clinicaltrials.gov/study/NCT06662006","created_at":"2025-02-26T07:54:41.562Z","updated_at":"2025-02-26T07:54:41.562Z","phase":"Phase 2","brief_title":"Nal-IRI/5-FU/LV Chemotherapy Combined with PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT As Second-line Therapy in Metastatic Pancreatic Cancer Patients","source_id_and_acronym":"NCT06662006","lead_sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Focus V (anlotinib) • Andewei (benmelstobart) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-10-28"},{"id":"d1fb7474-3dd7-44b8-b923-5fc52d65fdb6","acronym":"CLARITY-PanTumor01","url":"https://clinicaltrials.gov/study/NCT06219941","created_at":"2024-01-23T20:21:10.317Z","updated_at":"2024-07-02T16:34:26.279Z","phase":"Phase 2","brief_title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","source_id_and_acronym":"NCT06219941 - CLARITY-PanTumor01","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • leucovorin calcium • sonesitatug vedotin (AZD0901) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 01/19/2027","study_completion_date":" 01/19/2027","last_update_posted":"2024-06-13"},{"id":"cdacc270-2f12-47f1-ad69-ceb4bc5981ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03337087","created_at":"2021-01-18T16:29:08.233Z","updated_at":"2024-07-02T16:35:02.682Z","phase":"Phase 1/2","brief_title":"Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer","source_id_and_acronym":"NCT03337087","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Rubraca (rucaparib) • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/02/2018","start_date":" 11/02/2018","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 08/09/2025","study_completion_date":" 08/09/2025","last_update_posted":"2024-05-17"},{"id":"b2b1bd7e-227a-4bec-a55b-0537633e9eac","acronym":"Phenomenal","url":"https://clinicaltrials.gov/study/NCT03328884","created_at":"2021-01-18T16:26:17.952Z","updated_at":"2024-07-02T16:35:09.415Z","phase":"Phase 2","brief_title":"Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients","source_id_and_acronym":"NCT03328884 - Phenomenal","lead_sponsor":"MedSIR","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 05/02/2017","start_date":" 05/02/2017","primary_txt":" Primary completion: 08/31/2018","primary_completion_date":" 08/31/2018","study_txt":" Completion: 06/02/2025","study_completion_date":" 06/02/2025","last_update_posted":"2024-04-16"},{"id":"d2dc6321-01a2-4783-bd34-c34bd3bc5d9d","acronym":"GIANT","url":"https://clinicaltrials.gov/study/NCT04233866","created_at":"2021-01-18T20:35:40.191Z","updated_at":"2024-07-02T16:35:24.999Z","phase":"Phase 2","brief_title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","source_id_and_acronym":"NCT04233866 - GIANT","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" IL6 • UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["IL6 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 08/26/2020","start_date":" 08/26/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-12-28"},{"id":"0e08956e-36c5-4783-a5d1-7486d539cb85","acronym":"NAPOLI-2","url":"https://clinicaltrials.gov/study/NCT04005339","created_at":"2021-01-29T07:19:28.152Z","updated_at":"2024-07-02T16:35:25.289Z","phase":"Phase 2","brief_title":"NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer","source_id_and_acronym":"NCT04005339 - NAPOLI-2","lead_sponsor":"Georgetown University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/29/2019","start_date":" 07/29/2019","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2023-12-22"},{"id":"0ac2943a-4d67-4442-be19-a4505ba47397","acronym":"NEO-Nal- IRI","url":"https://clinicaltrials.gov/study/NCT03483038","created_at":"2021-01-18T17:09:31.835Z","updated_at":"2024-07-02T16:35:28.824Z","phase":"Phase 2","brief_title":"A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT03483038 - NEO-Nal- IRI","lead_sponsor":"University of Florida","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 09/16/2023","primary_completion_date":" 09/16/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-11-18"},{"id":"0b70ee73-7ffc-4235-87d1-c5de0491512b","acronym":"NCI-2019-07966","url":"https://clinicaltrials.gov/study/NCT04150640","created_at":"2021-01-18T20:14:45.162Z","updated_at":"2024-07-02T16:35:30.781Z","phase":"Phase 2","brief_title":"Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma","source_id_and_acronym":"NCT04150640 - NCI-2019-07966","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • 5-fluorouracil • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-11-01"},{"id":"499b3e91-baf0-42e6-80ef-87cd63f75cc1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05255666","created_at":"2022-02-24T13:52:52.986Z","updated_at":"2025-02-25T16:17:19.040Z","phase":"Phase 2","brief_title":"Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)","source_id_and_acronym":"NCT05255666","lead_sponsor":"Washington University School of Medicine","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/31/2023","start_date":" 07/31/2023","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2023-07-11"},{"id":"f62074f7-72f5-40d9-9af6-475d6423cc79","acronym":"","url":"https://clinicaltrials.gov/study/NCT05927857","created_at":"2023-07-03T16:10:24.736Z","updated_at":"2024-07-02T16:35:44.283Z","phase":"Phase 1/2","brief_title":"Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .","source_id_and_acronym":"NCT05927857","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-06-30"},{"id":"02a8700b-10e7-42d0-bae2-ac7f3065cf9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02022644","created_at":"2022-11-04T20:56:04.972Z","updated_at":"2024-07-02T16:35:44.339Z","phase":"Phase 1","brief_title":"Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma","source_id_and_acronym":"NCT02022644","lead_sponsor":"University of California, San Francisco","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 10/23/2014","start_date":" 10/23/2014","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2023-06-29"},{"id":"83b298fc-18f0-41c1-bee2-b338fb3c23d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05251038","created_at":"2022-02-22T13:52:40.179Z","updated_at":"2024-07-02T16:35:48.287Z","phase":"Phase 1/2","brief_title":"Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer","source_id_and_acronym":"NCT05251038","lead_sponsor":"Devalingam Mahalingam","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • Lumakras (sotorasib) • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 01/31/2023","study_completion_date":" 01/31/2023","last_update_posted":"2023-05-11"},{"id":"9b6d2eed-f184-4f87-922b-5c6538efff81","acronym":"T2317","url":"https://clinicaltrials.gov/study/NCT03712397","created_at":"2021-01-18T18:11:54.775Z","updated_at":"2024-07-02T16:35:50.946Z","phase":"Phase 2","brief_title":"Nanoliposomal Irinotecan in Head \u0026 Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy","source_id_and_acronym":"NCT03712397 - T2317","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" UGT1A1 • UGT1A9","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • UGT1A9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 12/24/2018","start_date":" 12/24/2018","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-04-11"},{"id":"311f4031-bd4c-41e9-8412-f0832d55f951","acronym":"LyRICX","url":"https://clinicaltrials.gov/study/NCT03764553","created_at":"2021-01-18T18:37:48.594Z","updated_at":"2024-07-02T16:35:59.028Z","phase":"Phase 2","brief_title":"Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer","source_id_and_acronym":"NCT03764553 - LyRICX","lead_sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2022-12-16"},{"id":"b50caec7-fd47-4333-bac0-e75fbafa887f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03883919","created_at":"2021-01-18T19:08:32.399Z","updated_at":"2024-07-02T16:36:02.965Z","phase":"Phase 1","brief_title":"Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy","source_id_and_acronym":"NCT03883919","lead_sponsor":"Washington University School of Medicine","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 03/23/2021","primary_completion_date":" 03/23/2021","study_txt":" Completion: 07/02/2022","study_completion_date":" 07/02/2022","last_update_posted":"2022-10-05"},{"id":"93f87e57-9718-4f29-b02f-982fc7f27fd8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04037241","created_at":"2021-01-18T19:48:33.373Z","updated_at":"2024-07-02T16:36:14.266Z","phase":"Phase 2b","brief_title":"Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer \u0026 Liver Metastases","source_id_and_acronym":"NCT04037241","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • gene-modified anti-CEA T cells"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2022-04-01"},{"id":"7cfa6f26-875f-4193-9aef-c545fb2ab82d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554707","created_at":"2021-01-18T17:29:50.207Z","updated_at":"2024-07-02T16:36:17.444Z","phase":"Phase 1","brief_title":"SGT-53 in Children With Recurrent or Progressive CNS Malignancies","source_id_and_acronym":"NCT03554707","lead_sponsor":"SynerGene Therapeutics, Inc.","biomarkers":" MGMT • MDM2 • CDKN1A","pipe":" | ","alterations":" ATRX mutation • MDM2 mutation","tags":["MGMT • MDM2 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • MDM2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • irinotecan • Onivyde (nanoliposomal irinotecan) • SGT-53"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-02-08"},{"id":"78686530-75c6-46e9-ac21-71b20816fc5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00940758","created_at":"2021-01-18T03:39:04.452Z","updated_at":"2024-07-02T16:37:23.750Z","phase":"Phase 1","brief_title":"Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy","source_id_and_acronym":"NCT00940758","lead_sponsor":"PharmaEngine","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • irinotecan • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2017-04-06"}]